Moshe Mishaeli

Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163

Susan Ellard, Mark Clemons, Karen A. Gelmon et al. · Journal of Clinical Oncology · 2009 · 261 citations

Medicine, Oncology, Pharmacology +16

BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors

Elizabeth Dudnik, Nir Peled, Hovav Nechushtan et al. · Journal of Thoracic Oncology · 2018 · 220 citations · Full text

Medicine, Molecular Genetics, Oncology +14

Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study

Sun Young Rha, Lucjan Wyrwicz, Nina Karaseva et al. · Journal of Clinical Oncology · 2025 · 29 citations

Medicine, Oncology, Perioperative Medicine +17

The Significance of Soluble lnterleukin-2, Soluble Interleuk in-2 Receptors, Soluble ICAM-1 and β<sub>2</sub>-Microglobulin in Breast Cancer Patients

Bernard Klein, I. Levin, B. Kfir et al. · Tumor Biology · 1995 · 26 citations

Medicine, Immunology, Oncology +17

Impact of the 12-Gene Colon Cancer Assay on Clinical Decision Making for Adjuvant Therapy in Stage II Colon Cancer Patients

Baruch Brenner, Ravit Geva, Megan Rothney et al. · Value in Health · 2015 · 20 citations · Full text

Medicine, Oncology, Chemotherapy +15